Analyst Research

Report Title Price
Provider: Sadif Analytics Prime
$10.00
Provider: ValuEngine, Inc.
$25.00
Provider: Finlabo SIM Spa
$10.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Bayer AG’s Bayer HealthCare Receives Approval For New Long-Term Contraceptive Skyla In U.S.


Thursday, 10 Jan 2013 02:38am EST 

Bayer AG announced that its unit, Bayer HealthCare has received approval from the United States Food and Drug Administration (FDA) for its new low dose levonorgestrelreleasing intrauterine system (IUS) called Skyla in the United States. The new IUS is placed in the uterus for the prevention of pregnancy for up to three years. Skyla is a small, flexible plastic T-shaped device containing 13.5 milligrams of a hormone called levonorgestrel. The size of the Skyla T-body is 28 millimeters x 30 millimeters, and its placement tube has a diameter of 3.8 millimeters. It slowly releases a low dose of levonorgestrel locally in the uterus and therefore small amounts of the hormone enter the bloodstream. 

Company Quote

147.33
 --
26 Nov 2014